BACKGROUND: Impaired fasting glucose (IFG) is a pre-diabetic state defined as a fasting plasma glucose (FPG) between 100 and 125 mg/dl. However, individuals in this group do not exhibit the same atherogenic risk. METHODS: The atherogenic profile of subjects with IFG >110 mg/dl (IFG110, n = 96) or <110 mg/dl (IFG100, n=131) were compared and the potential differential impact of the waist circumference analyzed. In addition, the same clinical variables were measured in 18 morbidly obese patients (8 males, 10 females; BMI 45.3 +/- 1.9 kg/m2) before and after weight loss following Roux-en-Y gastric bypass (RYGBP), in order to analyze the influence of the reduction in waist circumference on the improvement of the metabolic risk factors. RESULTS: Individuals in the IFG110 group showed decreased HDL-cholesterol levels together with an increased total cholesterol to HDL ratio (TC/HDL), accompanied by elevated homocysteine concentrations and white blood cell (WBC) count, and higher waist circumference (P<0.05 for all). Significant correlations between waist circumference and HDL-cholesterol (r=-0.200, P<0.05), TC/HDL (r=0.190, P<0.05), WBC count (r=0.299, P<0.05), and QUICKI (r=-0.375, P<0.0001) were observed. An almost 3-fold increase in the prevalence of T2DM in subjects in the IFG110 group as compared to IFG100 was observed. In the group of patients who underwent RYGBP, the reduction in waist circumference was significantly associated with the improvement in insulin sensitivity as evidenced by the QUICKI index (r=-0.582, P<0.05) and the reduction in TC/HDL (r=0.595, P<0.05). CONCLUSION: Waist circumference is related to metabolic risk factors associated with increased levels of IFG. Our data support that individuals with IFG >110 mg/dl and a high waist circumference should undergo an OGTT to exclude the presence of diabetes.
BACKGROUND: Impaired fasting glucose (IFG) is a pre-diabetic state defined as a fasting plasma glucose (FPG) between 100 and 125 mg/dl. However, individuals in this group do not exhibit the same atherogenic risk. METHODS: The atherogenic profile of subjects with IFG >110 mg/dl (IFG110, n = 96) or <110 mg/dl (IFG100, n=131) were compared and the potential differential impact of the waist circumference analyzed. In addition, the same clinical variables were measured in 18 morbidly obesepatients (8 males, 10 females; BMI 45.3 +/- 1.9 kg/m2) before and after weight loss following Roux-en-Y gastric bypass (RYGBP), in order to analyze the influence of the reduction in waist circumference on the improvement of the metabolic risk factors. RESULTS: Individuals in the IFG110 group showed decreased HDL-cholesterol levels together with an increased total cholesterol to HDL ratio (TC/HDL), accompanied by elevated homocysteine concentrations and white blood cell (WBC) count, and higher waist circumference (P<0.05 for all). Significant correlations between waist circumference and HDL-cholesterol (r=-0.200, P<0.05), TC/HDL (r=0.190, P<0.05), WBC count (r=0.299, P<0.05), and QUICKI (r=-0.375, P<0.0001) were observed. An almost 3-fold increase in the prevalence of T2DM in subjects in the IFG110 group as compared to IFG100 was observed. In the group of patients who underwent RYGBP, the reduction in waist circumference was significantly associated with the improvement in insulin sensitivity as evidenced by the QUICKI index (r=-0.582, P<0.05) and the reduction in TC/HDL (r=0.595, P<0.05). CONCLUSION: Waist circumference is related to metabolic risk factors associated with increased levels of IFG. Our data support that individuals with IFG >110 mg/dl and a high waist circumference should undergo an OGTT to exclude the presence of diabetes.
Authors: Gema Frühbeck; Alberto Diez-Caballero; M Jesús Gil; Inés Montero; Javier Gómez-Ambrosi; Javier Salvador; Javier A Cienfuegos Journal: Obes Surg Date: 2004-05 Impact factor: 4.129
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: M Ruano; V Silvestre; R Castro; M C G García-Lescún; E Aguirregoicoa; A Marco; A Rodríguez; G García-Blanch Journal: Obes Surg Date: 2006-05 Impact factor: 4.129
Authors: Javier Gómez-Ambrosi; Javier Salvador; Jose A Páramo; Josune Orbe; Jokin de Irala; Alberto Diez-Caballero; María J Gil; Javier A Cienfuegos; Gema Frühbeck Journal: Clin Biochem Date: 2002-06 Impact factor: 3.281
Authors: Peter C Tong; Ka-Fai Lee; Wing-Yee So; Margaret H Ng; Wing-Bun Chan; Matthew K Lo; Norman N Chan; Juliana C Chan Journal: Diabetes Care Date: 2004-01 Impact factor: 19.112
Authors: Tomasz Sledzinski; Elzbieta Goyke; Ryszard Tomasz Smolenski; Zbigniew Sledzinski; Julian Swierczynski Journal: Obes Surg Date: 2011-10 Impact factor: 4.129
Authors: Amaia Rodríguez; Sara Becerril; Víctor Valentí; Beatriz Ramírez; Marina Martín; Leire Méndez-Giménez; Andoni Lancha; Pablo del Sol Calderón; Victoria Catalán; María A Burrell; Javier Gómez-Ambrosi; Gema Frühbeck Journal: Obes Surg Date: 2012-02 Impact factor: 4.129
Authors: Javier Gómez-Ambrosi; Rafael Moncada; Víctor Valentí; Camilo Silva; Beatriz Ramírez; Victoria Catalán; Amaia Rodríguez; Patricia Andrada; Javier Escalada; Carlos Pastor; Javier A Cienfuegos; María J Gil; Javier Salvador; Gema Frühbeck Journal: Obes Surg Date: 2015-09 Impact factor: 4.129